Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in “real world” patients

Godoy-Ortiz, Ana; Plata, Y; Alcaide, Julia; Galeote, A.; Pajares, Bella; Sáez, E; Alba, E.; Sánchez-Muñoz, Alfonso

doi:10.1007/s12094-017-1808-x

Cited by 24 publications

(26 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Grade 2, grade 3, and grade 4 hematological adverse effects including neutropenia, leukopenia, and anemia and grade 2 and grade 3 nonhematological adverse effects including hypertension and gastrointestinal fistula were reported due to bevacizumab. The results of the current study were in parallel with the results of randomized trials, 9 phase II study, 3 a retrospective study, 10 phase III trials, 5,15 and CECILIA study. 16 Bevacizumab inhibits nitric oxide synthase, which leads to nonhematological adverse effects such as hypertension.…”

Section: Discussionsupporting

confidence: 63%

“…7 Hematological adverse effects were attributed to treatment-naive women. 3 The other nonhematological adverse effects, that is, gastrointestinal fistula, were due to recurrence status 10,16 of women (73%; 211/288). The addition of bevacizumab with the current chemotherapeutic regimen of paclitaxel plus carboplatin is not a well-tolerated treatment and increased vascular complications in women.…”

Section: Discussionmentioning

confidence: 99%

“…9 However, the phase II trial reported that the addition of bevacizumab to carboplatin-paclitaxel chemotherapy is effective for advanced or recurrent cervical cancer women with hematologic adverse effects. 3 Randomized clinical trials are generally accepted for predicting the efficacy and the safety of a new drug entity, 10 but they are conducted in highly selective patients. Therefore, there are gaps between clinical trials and clinical practice.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Paclitaxel, Carboplatin, and Bevacizumab in Advanced Cervical Cancer: A Treatment Response and Safety Analysis

et al. 2020

View full text Add to dashboard Cite

Background: Trials reported there are beneficial effects of the addition of bevacizumab to chemotherapy in advanced cervical cancer but might have adverse effects. The purposes of the study were to evaluate the treatment response and safety of the addition of bevacizumab to paclitaxel plus carboplatin in advanced cervical cancer women. Methods: Data on treatment response, adverse effects, and overall survival of women who received paclitaxel plus carboplatin every 3 weeks (ACT cohort, n = 161) or paclitaxel, carboplatin, and bevacizumab every 3 weeks (PCB cohort, n = 127) until disease progression or severe adverse events were collected and analyzed. Results: The treatment response of paclitaxel plus carboplatin increased on addition of bevacizumab ( P = .037). Neutropenia (grade ≥3, P = .001), leukopenia (grade 4, P = .041), anemia (grade ≥3, P = .031), hypertension (grade ≥2, P = .002), and gastrointestinal fistula (grade ≥2, P = 0.006) are reported in the PCB cohort. Women of ACT and PCB cohorts reported an overall survival of 20.11 ± 3.15 months and 24.52 ± 4.05 months, respectively. Conclusions: Addition of bevacizumab increases the treatment response of paclitaxel and carboplatin chemotherapy and overall survival of women with advanced cervical cancers, but it is not well tolerated.

show abstract

Section: Discussionsupporting

confidence: 63%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Paclitaxel, Carboplatin, and Bevacizumab in Advanced Cervical Cancer: A Treatment Response and Safety Analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The response rate was markedly higher among those patients who received bevacizumab than among those who did not (relative probability of a response, 1.35; 95% CI, 1.08-1.68; p = 0.008) [9]. On the basis of that study, Godoy-Ortiz et al [10] compared the efficacy and safety of chemotherapy with bevacizumab with their clinical patients and demonstrated the efficacy of bevacizumab as part of first-line treatment for advanced cervical cancer.…”

Section: Discussionmentioning

confidence: 78%

“…In that study, the addition of bevacizumab to combination chemotherapy for patients with recurrent metastatic cervical cancer was associated with an improved median OS. Bevacizumab is known to be efficient for patients with recurrent cervical cancer [9,10]. Combination therapy with bevacizumab could also be adapted for the treatment of small cell carcinoma, but the number of small cell carcinoma cases is insufficient to establish an effective treatment.…”

Section: Introductionmentioning

confidence: 99%

Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy

Nakao¹,

Tamauchi²,

Yoshikawa³

et al. 2020

Case Rep Oncol

View full text Add to dashboard Cite

We report a case of recurrent small cell carcinoma of the uterine cervix that showed a complete response to paclitaxel, carboplatin, and bevacizumab (TC + Bev) combination therapy. Small cell carcinoma of the uterine cervix is extremely rare, with an incidence of only 1.3% in Japan, and a poor outcome. The patient was a 62-year-old woman with a chief complaint of irregular vaginal bleeding. Magnetic resonance imaging showed a 10-cm irregular mass from the uterine corpus's posterior wall to the cervix. Abdominal total hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node sampling were performed for suspected uterine sarcoma. Histopathological findings revealed small cell carcinoma with lymph node metastasis. Although 6 cycles of etoposide + cisplatin were performed, para-aortic lymph node recurrence was found 3 months after chemotherapy. Subsequently, the patient received 8 cycles of TC + Bev, which eliminated the metastases. The patient is currently alive at 24 months.

show abstract

Palliative interventions for controlling vaginal bleeding in advanced cervical cancer

Eleje

Eke

Igberase

et al. 2019

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

BackgroundThis is an updated version of the original Cochrane review published in Issue 5, 2015.Cervical cancer is the fourth most common cancer among women worldwide, with estimated 569,847 new diagnoses and 311,365 deaths per year. However, incidence and stage at diagnosis vary greatly between geographic areas and are largely dependent on the availability of a robust population screening programme. For example, in Nigeria, advanced-stage disease at presentation is common (86% to 89.3% of new cases), whereas in the UK, only 21.9% of women present with International Federation of Gynaecology and Obstetrics (FIGO) stage II+ disease. Women with advanced cancer of the cervix o en need palliation for distressing symptoms, such as vaginal bleeding. Vaginal bleeding can be life threatening in advanced disease, with an incidence ranging from 0.7% to 100%. Bleeding is the immediate cause of death in 6% of women with cervical cancer and its management o en poses a challenge. Thus, vaginal bleeding remains a common consequence of advanced cervical cancer. Currently, there is no systematic review that addresses palliative interventions for controlling vaginal bleeding caused by advanced cervical cancer. A systematic evaluation of the available palliative interventions is needed to inform decision-making. ObjectivesTo evaluate the e icacy and safety of tranexamic acid, vaginal packing (with or without formalin-soaked packs), interventional radiology or other interventions compared with radiotherapy for palliative treatment of vaginal bleeding in women with advanced cervical cancer.

show abstract

Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in “real world” patients

Cited by 24 publications

References 18 publications

Paclitaxel, Carboplatin, and Bevacizumab in Advanced Cervical Cancer: A Treatment Response and Safety Analysis

Paclitaxel, Carboplatin, and Bevacizumab in Advanced Cervical Cancer: A Treatment Response and Safety Analysis

Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy

Palliative interventions for controlling vaginal bleeding in advanced cervical cancer

Contact Info

Product

Resources

About